Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815926 | 1.00 | IL6ST (0.34) | IL6STCACNA1GPPARATHRBFAAH | |
| SCHEMBL5818303 | 0.88 | IL6ST (0.38) | IL6STCACNA1GPPARAFAAHKMT2A | |
| SCHEMBL5818309 | 0.88 | IL6ST (0.38) | IL6STCACNA1GPPARAFAAHKMT2A | |
| SCHEMBL12212752 | 0.85 | CACNA1G (0.34) | IL6STCACNA1GPPARATHRBFAAH | |
| SCHEMBL4843154 | 0.83 | IL6ST (0.35) | IL6STCACNA1GPPARATHRBFAAH | |
| SCHEMBL4843167 | 0.83 | IL6ST (0.35) | IL6STCACNA1GPPARATHRBFAAH | |
| SCHEMBL5813999 | 0.82 | APLNR (0.35) | PPARAKMT2A | |
| SCHEMBL5814009 | 0.82 | APLNR (0.35) | PPARAKMT2A | |
| SCHEMBL12212753 | 0.80 | IL6ST (0.35) | IL6STCACNA1GPPARATHRBFAAH | |
| SCHEMBL12212754 | 0.79 | IL6ST (0.39) | IL6STPPARAFAAHELANECSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148218-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1312608-B1 | Discodermolide analogues and their pharmaceutical use | NOVARTIS AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK R (US) | 2005-04-14 | — | — | US | disclosed |
| US-6833367-B2 | A polyhydroxy-polymethyl-8-tridecenoic acid 8-lactone compounds, as antitumor agents, anticarcinogenic agents | NOVARTIS AC (CH) | 2004-12-21 | — | — | US | disclosed |
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | disclosed |
| EP-1312608-A2 | Discodermolide analogues and their pharmaceutical use | Novartis AG (CH) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153601-A1 | Certain substituted polyketides, pharmac eutical compositions containing them and their use in treating tumors | PBK, BCKDK, ETV6 | IL6ST 1570/4885CACNA1G 4227/4885PPARA 1242/4885 |
| US-20050080080-A1 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | PBK, HCCS, BCKDK | IL6ST 2521/4885CACNA1G 4781/4885PPARA 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.